REGN Stock Price Today (July 2026) — Regeneron Pharmaceuticals, Inc. Analysis & Key Metrics 2026-07-17
Regeneron Pharmaceuticals, Inc. (REGN) is trading at $676.69, down 0.33% today (as of July 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $833.31 (23.1% upside).
- Volatility remains elevated (25.65% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (19.00% YoY) alongside significant competitive pressures.
REGN Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Regeneron Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $57.39B
P/E Ratio
Forward P/E: 11.60
Revenue Growth
Year over Year
Analyst Target
+23.1% upside potential
Key Investor Questions About REGN
What investors need to know before buying
Based on current market data, REGN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 65.58)
- Fundamentals say: Caution warranted (high leverage concerns)
REGN's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for REGN investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $2.71B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, REGN stock traded between $521.00 and $821.11—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 25.65% annualized volatility and β=0.58, the stock exhibits low sensitivity to market moves—making REGN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?
Recent Performance Snapshot For Regeneron Pharmaceuticals Regeneron Pharmaceuticals (REGN) has drawn investor attention after a recent stretch of mixed share performance, with the stock up over the past month but lower over the past 3 months and year to date. The company, valued at about US$67.6b with last close near US$678.94, also reports annual revenue of US$14.9b and net income of US$4.4b from its portfolio of medicines across eye, inflammatory, cardiovascular, neurological, infectious...
Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.
Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill
It’s the first pill that lowers blood cholesterol far better than statins, medicines that a quarter of adults take to reduce their risk of heart attack and stroke.
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.
1 Large-Cap Stock with Exciting Potential and 2 We Turn Down
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Own Regeneron For Biotech Growth? Incyte Is Making Its Case.
For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.
Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2
Longleaf Partners, managed by Southeastern Asset Management, released its second-quarter 2026 investor letter for its “Partners Fund”. A copy of the letter can be downloaded here. The letter states that the portfolio holdings are attractive now based on both P/V and P/FCF metrics. However, the Fund returned 3.87% in the quarter, significantly lagging the S&P 500’s […]
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th
Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks on our list. TheFly reported on July 6 that HSBC reduced its price target on REGN to $800 from $990 while maintaining a Buy rating on the shares. The adjustment […]
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside
Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.
Frequently Asked Questions
Common investor questions about Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is currently trading at $676.69. The RSI (14-day) is at 65.6, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $833.31 implies 23.1% upside from current levels. Volatility is moderate at 25.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Regeneron Pharmaceuticals, Inc. (REGN): The trailing P/E ratio is 16.52, which is in line with broader market averages. The forward P/E is 11.60, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.08, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 2.19. Price-to-Sales is 4.67. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 28 analysts covering REGN, the consensus price target is $833.31. This represents a 23.1% upside from the current price of $676.69. The range spans from a low target of $641.00 to a high target of $1000.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Regeneron Pharmaceuticals, Inc. (REGN) pays a dividend with a current yield of approximately 56.00%. The annualized dividend rate is $3.58 per share. The payout ratio is 8.7%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-05-20T00:00:00.000Z.
Key risks for Regeneron Pharmaceuticals, Inc. (REGN) investors include: 1. Moderate volatility (25.7% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Regeneron Pharmaceuticals, Inc.'s (REGN) current debt and financial health profile: Total debt stands at $2.71B. The debt-to-equity ratio is 8.61, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.56, indicating strong short-term liquidity. The quick ratio is 2.84. The company holds $8.75B in cash and equivalents. Free cash flow is positive at $3.27B, providing a cushion for debt servicing and shareholder returns.